107188-74-9Relevant articles and documents
Pyrrolidine compounds, salts thereof, applications of compounds or salts thereof in nuclear magnetic probes and medicines, reagent, and medicine
-
Paragraph 0242; 0243; 0244, (2017/08/27)
The invention provides pyrrolidine compounds, salts thereof, applications of the compounds or the salts thereof in nuclear magnetic probes and medicines, a reagent, and a medicine. The benzamide methylpyrrolidine compounds have a chemical structure represented by general formula (I); and in the formula (I), R is selected from a methyl group, an ethyl group, a methoxy group, an ethoxy group and halogen, R is selected from a methyl group, an ethyl group, a methoxy group, an ethoxy group and halogen, R is selected from C1-5 alkyl groups and H, X is selected from C1-10 alkylene groups or is deleted, X is selected from -(CH2CH2O)n- (n is 1-5) or is deleted, X is selected from C1-5 alkyl groups, X is selected from oxygen, sulfur and a methylene group, and Ln is selected from Gd and Eu. The compounds have a gadolinium and europium chelating structure formed by combining with a dopamine D2 receptor and depending on intramolecular chelating groups, and specifically enhance the contrast of dopamine D2 receptor expression tissues on images in magnetic resonance imaging.
A general method for the synthesis of raclopride, FLB 457 and epidepride and corresponding desmethyl-precursors
Langer,Dolle,Halldin,Demphel,Vaufrey,Nagren,Lundkvist,Sandell,Crouzel
, p. S366-S368 (2007/10/03)
-
Potential antipsychotic agents. Part 8. Antidopaminergic properties of a potent series of 5-substituted (-)-(S)-N-[(1-ethylpyrrolidin-2-yl)methyl]-2,3-dimethoxybenzamides. Synthesis via common lithio intermediates
Hogberg,Strom,Hall,Ogren
, p. 417 - 425 (2007/10/02)
-
